课题基金 / 基金详情

A5146: A PHRASE II RANDOMIZED CONTROLLED TRIAL EVALUATING THE IMPACT OF THERAPEU

A5146: A PHRASE II RANDOMIZED CONTROLLED TRIAL EVALUATING THE IMPACT OF THERAPEU
A5146：评估治疗效果的 II 期随机对照试验
批准号：
7604206
负责人：
TIMOTHY J. WILKIN
金额：
$0.05万
依托单位：
WEILL MEDICAL COLL OF CORNELL UNIV
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
项目状态：
已结题
起止时间：
2007-04-01 至 2007-09-16
来源：
https://reporter.nih.gov/project-details/7604206
关键词：
Acquired Immunodeficiency SyndromeComputer Retrieval of Information on Scientific Projects DatabaseDoseDrug MonitoringFundingGoalsGrantInstitutionModificationPharmaceutical PreparationsProtease InhibitorRandomized Controlled TrialsResearchResearch PersonnelResourcesSourceTherapeuticUnited States National Institutes of Healthbaseexperienceimprovedresponse

项目摘要

项目成果

TIMOTHY J. WILKIN的其他基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 关于艾滋病 A5146的目标是根据治疗药物监测(TDM)的结果来确定修改蛋白酶抑制剂(PI)的剂量以优化PI药物浓度是否改善了PI经验受试者的病毒学反应，以及这种策略是否安全和耐受。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Regarding AIDS The goal of A5146 is to determine whether dose modification of protease inhibitors (PIs), based on the results of therapeutic drug monitoring (TDM) to optimize PI drug concentrations, improves virologic response in PI-experienced subjects and whether such a strategy is safe and tolerable.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Administrative and Coordinating Core
Clinical Trials Program
Central Laboratory Core
Administrative and Coordinating Core